Switch theme
Sign up to access all valuation multiples
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
2006
101
LTM Revenue $69.3M
Last FY EBITDA -$104M
$38.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fortress Biotech has a last 12-month revenue (LTM) of $69.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Fortress Biotech achieved revenue of $57.7M and an EBITDA of -$104M.
Fortress Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fortress Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $69.3M | XXX | $57.7M | XXX | XXX | XXX |
| Gross Profit | $43.1M | XXX | $36.8M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$104M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -181% | XXX | XXX | XXX |
| EBIT | -$97.0M | XXX | -$111M | XXX | XXX | XXX |
| EBIT Margin | -140% | XXX | -193% | XXX | XXX | XXX |
| Net Profit | -$48.7M | XXX | -$46.0M | XXX | XXX | XXX |
| Net Margin | -70% | XXX | -80% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fortress Biotech's stock price is $2.
Fortress Biotech has current market cap of $55.3M, and EV of $38.2M.
See Fortress Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38.2M | $55.3M | XXX | XXX | XXX | XXX | $-2.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fortress Biotech has market cap of $55.3M and EV of $38.2M.
Fortress Biotech's trades at 0.7x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Fortress Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fortress Biotech has a P/E ratio of -1.1x.
See valuation multiples for Fortress Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55.3M | XXX | $55.3M | XXX | XXX | XXX |
| EV (current) | $38.2M | XXX | $38.2M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFortress Biotech's last 12 month revenue growth is 47%
Fortress Biotech's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.5M for the same period.
Fortress Biotech's rule of 40 is -111% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fortress Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fortress Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -181% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -111% | XXX | -135% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 257% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fortress Biotech acquired XXX companies to date.
Last acquisition by Fortress Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Fortress Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fortress Biotech founded? | Fortress Biotech was founded in 2006. |
| Where is Fortress Biotech headquartered? | Fortress Biotech is headquartered in United States of America. |
| How many employees does Fortress Biotech have? | As of today, Fortress Biotech has 101 employees. |
| Who is the CEO of Fortress Biotech? | Fortress Biotech's CEO is Dr. Lindsay A. Rosenwald, M.D.. |
| Is Fortress Biotech publicy listed? | Yes, Fortress Biotech is a public company listed on NAS. |
| What is the stock symbol of Fortress Biotech? | Fortress Biotech trades under FBIO ticker. |
| When did Fortress Biotech go public? | Fortress Biotech went public in 2011. |
| Who are competitors of Fortress Biotech? | Similar companies to Fortress Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fortress Biotech? | Fortress Biotech's current market cap is $55.3M |
| What is the current revenue of Fortress Biotech? | Fortress Biotech's last 12 months revenue is $69.3M. |
| What is the current revenue growth of Fortress Biotech? | Fortress Biotech revenue growth (NTM/LTM) is 47%. |
| What is the current EV/Revenue multiple of Fortress Biotech? | Current revenue multiple of Fortress Biotech is 0.6x. |
| Is Fortress Biotech profitable? | Yes, Fortress Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
